羊膜市场 - 副产品（冷冻保存、冷冻干燥）、应用（手术伤口、眼科、干细胞生物学、再生医学、产前诊断）、最终用途（医院、专科诊所） - 全球预测，2024 年 - 2032 年

由于组织工程和再生医学技术的进步，以及羊膜产品的日益普及，全球羊膜市场从 2024 年到 2032 年的复合年增长率将达到 11.2%。这些创新为各个医学专业的伤口癒合和组织修復提供了有前景的解决方案。随着在眼科、骨科和伤口护理领域的广泛应用，羊膜因其再生特性而越来越受到青睐。随着人们认识的提高和医疗保健专业人员亲眼目睹其好处，对这些先进疗法的需求将推动羊膜产业的成长。

例如，2022 年 11 月，Versaa 推出了 Biovance 3L 眼部三层人羊膜，为眼科应用提供先进的再生能力。

羊膜市场根据产品、应用、最终用途和地区进行分类。

由于眼部疾病盛行率上升以及眼科手术越来越多地采用羊膜产品，到 2032 年，眼科领域将获得可观的效益。随着眼部护理技术的进步，这些膜可以有效治疗角膜溃疡和结膜炎等疾病。眼科医生青睐这些产品，因为它们具有再生特性和促进癒合的能力。随着对创新眼部护理解决方案的需求上升，眼科领域将保持其在羊膜行业的主导地位。

由于致力于先进伤口护理和再生医学的专业诊所数量不断增加，到 2032 年，专业诊所领域的羊膜产业规模将获得可观的估值。这些诊所提供使用羊膜产品治疗各种病症的针对性方法。随着患者对微创手术的偏好激增以及这些膜在伤口癒合中的有效性，专科诊所处于最前线。他们对提供专业护理的承诺将大大有助于他们在市场上的主导地位。

受手术数量增加、人们对羊膜产品益处的认识不断提高以及医疗基础设施不断发展等因素的推动，亚太地区羊膜行业在 2024 年至 2032 年间将以显着的复合年增长率增长。中国和印度等国家是这一成长的主要贡献者，它们拥有庞大的患者群体和不断扩大的医疗设施。此外，该地区对研发的关注将进一步巩固亚太地区作为羊膜市场关键贡献者的地位。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 再生医学需求不断成长
    • 慢性伤口的发生率上升
    • 生物技术与组织工程的进步
    • 提高羊膜产品的认知度与接受度
  • 产业陷阱与挑战
    • 羊膜产品保存期限有限
    • 严格的监理政策
• 成长潜力分析
• 技术景观
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

• 主要趋势
• 冷冻保存
• 冻干的

第 6 章：市场估计与预测：按应用划分，2018 年 - 2032 年

• 主要趋势
• 手术伤口
• 眼科
• 干细胞生物学
• 再生医学
• 产前诊断
• 其他应用

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 医院
• 门诊手术中心 (ASC)
• 专科诊所
• 研究和学术机构
• 其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Alliqua BioMedical Inc.
• Alynx, Co.
• Amnio Technology, LLC
• Applied Biologics LLC
• BioTissue Holdings Inc.
• Corza Health, Inc.
• Integra LifeSciences Corporation
• Organogensis, Inc.
• Skye Biologics, Inc.
• TissueTech, Inc.

Global Amniotic Membrane Market will register 11.2% CAGR from 2024 to 2032, attributed to advancements in tissue engineering and regenerative medicine technologies, coupled with the growing adoption of amniotic membrane products. These innovations offer promising solutions for wound healing and tissue repair across various medical specialties. With versatile applications in ophthalmology, orthopedics, and wound care, amniotic membranes are increasingly favored for their regenerative properties. As awareness grows and healthcare professionals witness the benefits firsthand, the demand for these advanced therapies will fuel the growth of the amniotic membrane industry.

For instance, in November 2022, Versea introduced the Biovance 3L ocular tri-layer human amniotic membrane, offering advanced regenerative capabilities for ophthalmic applications.

The amniotic membrane market is classified based on product, application, end-use, and region.

The ophthalmology segment will amass considerable gains by 2032, propelled by the rising prevalence of ocular disorders and the increasing adoption of amniotic membrane products for ophthalmic surgeries. With advancements in eye care technology, these membranes offer effective treatment for conditions like corneal ulcers and conjunctivitis. Ophthalmologists favor these products for their regenerative properties and ability to promote healing. As demand for innovative eye care solutions rises, the ophthalmology segment will maintain its dominance in the amniotic membrane industry.

The amniotic membrane industry size from the specialty clinics segment will secure a substantial valuation by 2032 due to the increasing number of specialized clinics dedicated to advanced wound care and regenerative medicine. These clinics offer a focused approach to treating various conditions using amniotic membrane products. With a surge in patient preference for minimally invasive procedures and the effectiveness of these membranes in wound healing, specialty clinics are at the forefront. Their commitment to providing specialized care will contribute significantly to their dominance in the market.

Asia Pacific amniotic membrane industry will grow at a notable CAGR between 2024 and 2032, fueled by factors such as the rising number of surgeries, increasing awareness about the benefits of amniotic membrane products, and the growing healthcare infrastructure. Countries like China and India are key contributors to this growth, with their large patient populations and expanding healthcare facilities. Additionally, the region's focus on research and development will further solidify Asia Pacific's position as the pivotal contributor to the amniotic membrane market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing demand for regenerative medicine
    • 3.2.1.2 Rising incidence of chronic wounds
    • 3.2.1.3 Advancements in biotechnology and tissue engineering
    • 3.2.1.4 Increasing awareness and acceptance of amniotic membrane products
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited shelf life of amniotic membrane products
    • 3.2.2.2 Stringent regulatory polices
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Cryopreserved
• 5.3 Lyophilized

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Surgical wounds
• 6.3 Ophthalmology
• 6.4 Stem cell biology
• 6.5 Regenerative medicine
• 6.6 Prenatal diagnosis
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers (ASCs)
• 7.4 Specialty clinics
• 7.5 Research and academic institutes
• 7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Alliqua BioMedical Inc.
• 9.2 Alynx, Co.
• 9.3 Amnio Technology, LLC
• 9.4 Applied Biologics LLC
• 9.5 BioTissue Holdings Inc.
• 9.6 Corza Health, Inc.
• 9.7 Integra LifeSciences Corporation
• 9.8 Organogensis, Inc.
• 9.9 Skye Biologics, Inc.
• 9.10 TissueTech, Inc.